Samsung Bioepis' Three Biosimilars Achieve 870 Billion KRW Sales in Europe Last Year

Europe Annual Sales Increase by 7.8%

Samsung Bioepis's autoimmune disease treatments Benepali, Imraldi, Flixabi (Photo by Samsung Bioepis)

[Asia Economy Reporter Kim Ji-hee] Three biosimilars for autoimmune disease treatments developed by Samsung Bioepis performed well in the European market last year, recording sales close to 800 million dollars.

Samsung Bioepis' European marketing partner, Biogen, announced the 2020 annual results including this information on the 3rd (local time in the U.S.). According to the earnings report, sales of Samsung Bioepis' autoimmune disease treatments Benepali, Imraldi, and Flixabi in the European market reached 795.8 million dollars (approximately 866 billion KRW), a 7.8% increase compared to the previous year.

Samsung Bioepis explained, "Despite volatility caused by COVID-19 and intensifying market competition, product sales have continuously expanded based on supply stability. Although there was a temporary market contraction last year due to a decrease in drug prescriptions amid the COVID-19 impact, we showed growth in sales and sales volume compared to the previous year through stable product supply chain management during the normalization process of the healthcare system."

The flagship product Benepali (Enbrel biosimilar) recorded annual sales of 481.6 million dollars (approximately 524 billion KRW) in 2020. On a quarterly average, it showed sales of about 120 million dollars and maintained over 40% market share across Europe.

Imraldi (Humira biosimilar), competing with a total of five products in the European market, achieved annual sales of 216.3 million dollars, a 17.6% increase from the previous year. Currently, Humira biosimilars launched in Europe include Imraldi, Amgen's Amgevita, Sandoz's Hyrimoz, Amylin's Hulio, and Fresenius Kabi's Idacio.

Flixabi (Remicade biosimilar) doubled its annual sales volume and market share, recording annual sales of 97.9 million dollars, a 43.8% increase compared to the previous year.

A Samsung Bioepis official said, "We will strive to further strengthen our leadership in the European autoimmune disease treatment market through continuous expansion of product sales utilizing a diverse product portfolio."

This content was produced with the assistance of AI translation services.